A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention
神经炎症抑郁症的转化研究:了解新型药物干预的机制和评估
基本信息
- 批准号:10273563
- 负责人:
- 金额:$ 2.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-05 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AftercareAnti-Inflammatory AgentsAntidepressive AgentsAstrocytesBrainChronicDataDepressed moodDiseaseDisease remissionEnrollmentEvaluationFunctional disorderHumanIndividualInflammatoryInterventionMajor Depressive DisorderMeasuresMedicineMental DepressionMessenger RNAMicrogliaMorphologyMusNeurogliaOutcomeOuter Mitochondrial MembraneParticipantPathologyPatient RecruitmentsPatientsPharmaceutical PreparationsPharmacologyPhenotypePositron-Emission TomographyPrefrontal CortexProteinsProxyPsychiatryRodentStressSubgroupTestingWild Type Mouseantidepressant effectbiological heterogeneitycelecoxibclinically relevantdepression modeldepressive symptomsdisorder subtypeimprovedin vivoinflammatory markermicroPETmouse modelneuroinflammationnovelresponsesocial defeattargeted treatmenttranslational study
项目摘要
Major depressive disorder (MDD) is one of the most heterogeneous disorders in psychiatry and first line
treatments are inadequate for the majority of patients, likely because they do not target an individual’s subtype.
Improving our understanding of MDD subtypes will allow us to (1) identify treatments that target subtype-specific
pathophysiology and (2) determine which subgroup of MDD patients will best respond to these treatments, thus
improving antidepressant outcomes. In a neuroinflammatory subtype, MDD may manifest via chronic
neuroinflammation. The translocator protein (TSPO), located on the outer mitochondrial membrane of microglia
and astrocytes, is regarded as a marker of this neuroinflammation and can be measured in vivo by positron
emission tomography (PET). In support of a neuroinflammatory subtype of MDD, TSPO, measured by PET, was
found to be elevated by 30% on average in the prefrontal cortex (PFC) in MDD relative to healthy individuals.
Further, we have preliminary data from a repeated social defeat stress mouse model that shows elevated PFC
TSPO and other elevated neuroinflammation markers in a subset of ‘depressed’, non-resilient mice, and that this
phenotype is reversed by elimination of TSPO expressing glial cells! To parallel this effect in humans, brain-
penetrant anti-inflammatory medications such as celecoxib can be used. Celecoxib has antidepressant effects
in MDD; however, the observed effect sizes are highly variable, likely reflecting the biological heterogeneity of
MDD. We hypothesize that anti-inflammatory treatments such as celecoxib will be most effective in those with
the neuroinflammatory subtype of MDD and that the mechanism of antidepressant action is through a reduction
of neuroinflammation. We will test these hypotheses in parallel studies in humans in rodents. For the human
aim, we will take advantage of an ongoing study of celecoxib efficacy currently being performed at Stony Brook
Medicine (PI: Parsey) by recruiting participants who are already being treated with celecoxib (8 weeks,
400mg/day). 53 MDD participants will be enrolled, with 42 expected to complete the study involving TSPO PET
imaging before and after treatment. We hypothesize that higher PFC TSPO (as measured by PET) prior to
treatment will be correlated with better response to celecoxib and further, that reductions in PFC TSPO will be
correlated to depression improvement after adjusting for covariates. In a parallel study in rodents, we
hypothesize that PFC TSPO and other CNS inflammation markers in our repeated social defeat stress mouse
model of depression will be elevated as measured by microPET, quantitative protein/mRNA level analysis, and
reactive microglial morphology, when compared to wild type mice. Further, we hypothesize that elevated PFC
TSPO and other neuroinflammatory markers will be reduced after celecoxib treatment. If mouse and human
studies do not agree, this suggests that TSPO PET provides a clinically relevant proxy of neuroinflammation.
However, if our hypotheses are confirmed, this would validate that TSPO is a marker of the neuroinflammatory
MDD subtype and a target of treatment.
重度抑郁症 (MDD) 是精神病学和一线疾病中最具异质性的疾病之一
治疗对于大多数患者来说是不够的,可能是因为它们不针对个体的亚型。
提高我们对 MDD 亚型的理解将使我们能够 (1) 确定针对亚型特异性的治疗方法
病理生理学和 (2) 确定 MDD 患者的哪个亚组对这些治疗反应最好,从而
改善抗抑郁效果。在神经炎症亚型中,MDD 可能通过慢性表现
神经炎症。易位蛋白(TSPO),位于小胶质细胞线粒体外膜上
和星形胶质细胞,被认为是这种神经炎症的标志物,可以通过正电子在体内测量
发射断层扫描(PET)。为了支持 MDD 的神经炎症亚型,通过 PET 测量的 TSPO
研究发现,与健康人相比,重度抑郁症患者的前额皮质 (PFC) 平均升高 30%。
此外,我们从重复的社交失败应激小鼠模型中获得了初步数据,该模型显示 PFC 升高
在“抑郁”、无弹性的小鼠子集中,TSPO 和其他神经炎症标记物升高,并且这
通过消除表达 TSPO 的神经胶质细胞来逆转表型!为了与人类产生类似的效果,大脑
可以使用塞来昔布等渗透性抗炎药物。塞来昔布具有抗抑郁作用
在MDD中;然而,观察到的效应大小变化很大,可能反映了生物异质性
医学博士。我们假设塞来昔布等抗炎治疗对于患有以下疾病的患者最有效
MDD 的神经炎症亚型,抗抑郁作用的机制是通过减少
神经炎症。我们将在人类和啮齿动物身上进行平行研究来检验这些假设。对于人类来说
目标,我们将利用石溪目前正在进行的塞来昔布疗效研究
医学(PI:Parsey),招募已经接受塞来昔布治疗的参与者(8周,
400毫克/天)。将招募 53 名 MDD 参与者,其中 42 名预计将完成涉及 TSPO PET 的研究
治疗前和治疗后的影像学检查。我们假设在
治疗将与塞来昔布的更好反应相关,并且进一步,PFC TSPO 的减少将
调整协变量后与抑郁症改善相关。在一项针对啮齿动物的平行研究中,我们
假设我们反复社交失败应激小鼠中的 PFC TSPO 和其他中枢神经系统炎症标记物
通过 microPET、定量蛋白质/mRNA 水平分析以及
与野生型小鼠相比,反应性小胶质细胞形态。此外,我们假设 PFC 升高
塞来昔布治疗后 TSPO 和其他神经炎症标志物会减少。如果老鼠和人类
虽然研究并不同意,但这表明 TSPO PET 提供了神经炎症的临床相关代理。
然而,如果我们的假设得到证实,这将验证 TSPO 是神经炎症的标志物
MDD 亚型和治疗目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christine Delorenzo其他文献
Christine Delorenzo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christine Delorenzo', 18)}}的其他基金
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention
神经炎症抑郁症的转化研究:了解新型药物干预的机制和评估
- 批准号:
10375542 - 财政年份:2020
- 资助金额:
$ 2.19万 - 项目类别:
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention
神经炎症抑郁症的转化研究:了解新型药物干预的机制和评估
- 批准号:
10159330 - 财政年份:2020
- 资助金额:
$ 2.19万 - 项目类别:
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention
神经炎症抑郁症的转化研究:了解新型药物干预的机制和评估
- 批准号:
10588196 - 财政年份:2020
- 资助金额:
$ 2.19万 - 项目类别:
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention - Diversity Administrative supplement for Kimberly Nnah
神经炎症性抑郁症的转化研究:了解新型药物干预的机制和评估 - Kimberly Nnah 的多样性行政补充
- 批准号:
10721922 - 财政年份:2020
- 资助金额:
$ 2.19万 - 项目类别:
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythmmisalignment and depression: Implications for treatment
代谢型谷氨酸受体亚型 5 在昼夜节律失调和抑郁中的作用:对治疗的影响
- 批准号:
10677531 - 财政年份:2018
- 资助金额:
$ 2.19万 - 项目类别:
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythmmisalignment and depression: Implications for treatment
代谢型谷氨酸受体亚型 5 在昼夜节律失调和抑郁中的作用:对治疗的影响
- 批准号:
10226836 - 财政年份:2018
- 资助金额:
$ 2.19万 - 项目类别:
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythm misalignment and depression: Implications for treatment
代谢型谷氨酸受体亚型 5 在昼夜节律失调和抑郁中的作用:对治疗的影响
- 批准号:
9766372 - 财政年份:2018
- 资助金额:
$ 2.19万 - 项目类别:
Advancing Personalized Antidepressant Treatment Using PET/MRI
使用 PET/MRI 推进个性化抗抑郁治疗
- 批准号:
9045708 - 财政年份:2015
- 资助金额:
$ 2.19万 - 项目类别:
Advancing Personalized Antidepressant Treatment Using PET/MRI
使用 PET/MRI 推进个性化抗抑郁治疗
- 批准号:
8886319 - 财政年份:2015
- 资助金额:
$ 2.19万 - 项目类别:
Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET Ligand
新型代谢型谷氨酸受体亚型 5 PET 配体的表征
- 批准号:
8261691 - 财政年份:2011
- 资助金额:
$ 2.19万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 2.19万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 2.19万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 2.19万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 2.19万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 2.19万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 2.19万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 2.19万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 2.19万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 2.19万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 2.19万 - 项目类别:














{{item.name}}会员




